HL-60 granulocytic/neutrophil-like differentiation

• Use HL-60 cells cultured in RPMI-1640 with 10% FBS or serum-free X-VIVO 15 when the downstream readout is NET production; use ATRA at 1 µM, DMSO at 1-1.3%, PBS for washing/staining, and PMA or calcium ionophore only when ROS or NET function is being tested^[1][5][6][8].

• Use anti-CD11b to measure granulocytic differentiation, anti-CD71 to measure loss of proliferative phenotype, PI for cell-cycle/sub-G1 analysis, May-Grünwald-Giemsa or Wright-Giemsa staining for morphology, pHrodo particles for phagocytosis, NBT for oxidative burst, and CD16/CD66b/CD62L only as optional phenotype markers because their expression varies across reports^[1][3][6][8].

• Use a humidified 37°C, 5% CO₂ incubator for HL-60 culture, standard cell-culture equipment for suspension-cell handling, a flow cytometer for CD-marker, apoptosis, ROS, and cell-cycle measurements, a light microscope for cytology and NBT scoring, and a fluorescence microscope or plate reader only when NET or fluorescent phagocytosis assays are performed^[1][3][5][6].

• Maintain HL-60 cells in suspension culture and use cultures before extensive passaging; Guo et al. used cells passaged no more than 15 times, and Millius and Weiner describe differentiation in culture medium plus 1.3% DMSO for approximately 5 days before migration assays^[5][6].

• Prepare differentiation medium by adding 1 µM ATRA plus 1% DMSO for the main combined protocol; literature also reports DMSO-only differentiation at 1-1.3% for 3-7 days, ATRA-only differentiation at 0.1-1 µM for 1-5 days, and 1.25% DMSO or 1 µM ATRA for 3-7 days in serum-containing or X-VIVO medium^{[1][3][4][5][6][8]}.

• Seed HL-60 cells into fresh culture medium and start differentiation by adding 1 µM ATRA plus 1% DMSO, then incubate for 5 days at 37°C with 5% CO₂; this is the preferred literature-supported condition for neutrophil-like differentiation with high CD11b, low CD71, neutrophil-like morphology, and increased phagocytosis^[1].

• For comparator conditions, include untreated HL-60 cells, ATRA-only cells, and DMSO-only cells; ATRA alone and DMSO alone can induce granulocytic features, but the combined ATRA+DMSO condition showed stronger differentiation than either single agent in the cited 5-day comparison^{[1][3][4][6][8]}.

• At day 5, harvest suspension cells and assess morphology by May-Grünwald-Giemsa or Wright-Giemsa staining, because differentiated cells have been evaluated by decreased nucleus/cytoplasm ratio, kidney-like or segmented nuclei, and reduced basophilic cytoplasm^[1][8].

• Analyze surface phenotype by flow cytometry for CD11b and CD71; in the cited combined protocol, ATRA+DMSO produced approximately 81.4% CD11b-positive and 6% CD71-positive cells at day 5, while DMSO alone produced lower CD11b positivity and higher CD71 positivity^[1].

• Assess function using phagocytosis, NBT reduction, ROS formation, or NET assays only when these are required for the study aim; pHrodo phagocytosis, NBT reduction after stimulation, ROS flow cytometry, PicoGreen NET quantification, and fluorescence microscopy have all been used as readouts in differentiated HL-60 studies^[1][3][6].

• Interpret successful granulocytic/neutrophil-like differentiation as concordant evidence of increased CD11b, reduced CD71 or reduced proliferation, neutrophil-like morphology, and increased phagocytic or oxidative-burst function, rather than relying on a single marker^{[1][2][3][4][6][7][8]}.

• Use untreated HL-60 cells as the negative control and, where available, freshly isolated human neutrophils as a positive biological comparator for morphology, CD16/CD66b, CD62L, phagocytosis, ROS, or NET-related readouts^[1][6].

• Use biological replicates when quantifying differentiation; the cited studies report repeated independent experiments, including n ≥ 3 for marker/function assays and larger replicate numbers for cell density, cell-cycle, and apoptosis analyses in the ATRA+DMSO study^[1][6][8].

Problem: CD11b induction is weak after differentiation.

• Possible Cause: The inducer condition is insufficient for the intended neutrophil-like phenotype.
• Literature-supported Solution: Use the 5-day combined 1 µM ATRA plus 1% DMSO condition when the goal is high CD11b and low CD71, because ATRA or DMSO alone gave weaker differentiation in the direct comparison^[1].

Problem: CD16 or CD66b is absent despite CD11b induction.

• Possible Cause: HL-60 cells do not consistently express CD16/CD66b after differentiation.
• Literature-supported Solution: Do not define failure solely by CD16/CD66b; prioritize CD11b, CD71 loss, morphology, and functional readouts, and use primary neutrophils as a positive comparator when testing CD16/CD66b^[1][6][8].

Problem: NET production is low.

• Possible Cause: Differentiation medium and inducer condition influence NET readouts.
• Literature-supported Solution: For NET-focused experiments, use the Guo et al. conditions showing that 5-day differentiation in serum-free X-VIVO medium enhanced NET production, with DMSO-dHL-60 supporting ROS-high PMA-induced NETosis and ATRA-dHL-60 supporting calcium-ionophore-associated citH3 responses^[6].

Problem: DMSO-differentiated HL-60 cells do not behave like primary neutrophils in trafficking/rolling assays.

• Possible Cause: DMSO exposure alters HL-60 rolling behavior over time.
• Literature-supported Solution: Validate rolling behavior directly for the chosen differentiation duration, because DMSO-treated HL-60 cells were reported to show time-dependent changes in P-selectin-mediated rolling velocity^[9].